Ignet

Gene Information

Gene symbol: GPR55

Gene name: G protein-coupled receptor 55

HGNC ID: 4511

Related Genes

#	Gene Symbol	Number of hits
1	ABCA4	1 hits
2	ABCC1	1 hits
3	AKT1	1 hits
4	CD9	1 hits
5	CNR1	1 hits
6	CNR2	1 hits
7	GPRC5C	1 hits
8	INS	1 hits
9	MAPK1	1 hits
10	MAPK6	1 hits
11	PLA2G4A	1 hits
12	TRPV1	1 hits

Related Sentences

#	PMID	Sentence
1	20838378	Indeed we demonstrate that LPI is able to induce calcium mobilization and activation of Akt and extracellular signal-regulated kinase (ERK)1/2 in these cells and that both pharmacological blockade of GPR55 and its downregulation using specific small interfering RNA strongly inhibits these processes.
2	20838378	We further identify an autocrine loop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-binding cassette transporter ABCC1/MRP1, and is then able to initialize cascades downstream of GPR55.
3	20838378	Indeed we demonstrate that LPI is able to induce calcium mobilization and activation of Akt and extracellular signal-regulated kinase (ERK)1/2 in these cells and that both pharmacological blockade of GPR55 and its downregulation using specific small interfering RNA strongly inhibits these processes.
4	20838378	We further identify an autocrine loop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-binding cassette transporter ABCC1/MRP1, and is then able to initialize cascades downstream of GPR55.
5	21220919	Endogenous endocannabinoids bind to cannabinoid receptors; namely CB1, CB2, TRPV1 and GPR55, to activate intracellular pathways that control many cellular functions.
6	21220919	Characterisation of HK2 cells demonstrated that mRNA and protein for CB1, CB2, TRPV1 and GPR55 occurs in these cells.
7	21220919	In general, treatment with CB1 antagonist AM-251, reduces hypertrophy while treatment with CB2 (AM-630) and TRPV1 (SB-366791) antagonists increases hypertrophy.
8	21220919	Endogenous endocannabinoids bind to cannabinoid receptors; namely CB1, CB2, TRPV1 and GPR55, to activate intracellular pathways that control many cellular functions.
9	21220919	Characterisation of HK2 cells demonstrated that mRNA and protein for CB1, CB2, TRPV1 and GPR55 occurs in these cells.
10	21220919	In general, treatment with CB1 antagonist AM-251, reduces hypertrophy while treatment with CB2 (AM-630) and TRPV1 (SB-366791) antagonists increases hypertrophy.
11	21885477	We found high Gpr55 mRNA content in pancreatic islets and considerable protein distribution in insulin-secreting β-cells.
12	21885477	Activation of GPR55 by the agonist O-1602 increased calcium transients (P<0.01) and insulin secretion (P<0.001) stimulated by glucose.
13	21885477	Indeed, acute in vivo experiments showed that GPR55 activation increases glucose tolerance (P<0.05) and plasma insulin levels (P<0.05), suggesting an in vivo physiological relevance of GPR55 systemic stimulation.
14	21885477	Taken together, these results reveal the expression of GPR55 receptors in the endocrine pancreas as well as its function at stimulus-secretion coupling of insulin secretion, suggesting a role in glucose homeostasis.
15	21885477	We found high Gpr55 mRNA content in pancreatic islets and considerable protein distribution in insulin-secreting β-cells.
16	21885477	Activation of GPR55 by the agonist O-1602 increased calcium transients (P<0.01) and insulin secretion (P<0.001) stimulated by glucose.
17	21885477	Indeed, acute in vivo experiments showed that GPR55 activation increases glucose tolerance (P<0.05) and plasma insulin levels (P<0.05), suggesting an in vivo physiological relevance of GPR55 systemic stimulation.
18	21885477	Taken together, these results reveal the expression of GPR55 receptors in the endocrine pancreas as well as its function at stimulus-secretion coupling of insulin secretion, suggesting a role in glucose homeostasis.
19	21885477	We found high Gpr55 mRNA content in pancreatic islets and considerable protein distribution in insulin-secreting β-cells.
20	21885477	Activation of GPR55 by the agonist O-1602 increased calcium transients (P<0.01) and insulin secretion (P<0.001) stimulated by glucose.
21	21885477	Indeed, acute in vivo experiments showed that GPR55 activation increases glucose tolerance (P<0.05) and plasma insulin levels (P<0.05), suggesting an in vivo physiological relevance of GPR55 systemic stimulation.
22	21885477	Taken together, these results reveal the expression of GPR55 receptors in the endocrine pancreas as well as its function at stimulus-secretion coupling of insulin secretion, suggesting a role in glucose homeostasis.
23	21885477	We found high Gpr55 mRNA content in pancreatic islets and considerable protein distribution in insulin-secreting β-cells.
24	21885477	Activation of GPR55 by the agonist O-1602 increased calcium transients (P<0.01) and insulin secretion (P<0.001) stimulated by glucose.
25	21885477	Indeed, acute in vivo experiments showed that GPR55 activation increases glucose tolerance (P<0.05) and plasma insulin levels (P<0.05), suggesting an in vivo physiological relevance of GPR55 systemic stimulation.
26	21885477	Taken together, these results reveal the expression of GPR55 receptors in the endocrine pancreas as well as its function at stimulus-secretion coupling of insulin secretion, suggesting a role in glucose homeostasis.
27	23679955	Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
28	23679955	The orphan G-protein-coupled receptor GPR55, which is activated by 1-lysophosphatidylinositol and interacts with cannabinoid (CB) receptor ligands, has been proposed as a new potential drug target for the treatment of diabetes, Parkinson's disease, neuropathic pain, and cancer.
29	23679955	Selectivity versus the related receptors CB1, CB2, and GPR18 was assessed.
30	23679955	Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
31	23679955	The orphan G-protein-coupled receptor GPR55, which is activated by 1-lysophosphatidylinositol and interacts with cannabinoid (CB) receptor ligands, has been proposed as a new potential drug target for the treatment of diabetes, Parkinson's disease, neuropathic pain, and cancer.
32	23679955	Selectivity versus the related receptors CB1, CB2, and GPR18 was assessed.